Merck is splitting its human health segment into two units to prepare for the 2028 Keytruda patent expiry. One unit will focus on cancer drugs, the other on specialty care. This restructuring aims to better position Merck for revenue headwinds and competition expected when its top-selling therapy loses exclusivity.